• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

产碳青霉烯酶肺炎克雷伯菌 ST307 的基因组特征揭示了在阿根廷布宜诺斯艾利斯的多次传入。

Genomic characterization of carbapenemase-producing Klebsiella pneumoniae ST307 revealed multiple introductions in Buenos Aires, Argentina.

机构信息

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Ciudad Autónoma de Buenos Aires, Argentina; CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Ciudad Autónoma de Buenos Aires, Argentina.

University of Genoa, Department of Surgical Sciences and Integrated Diagnostics (DISC), Genoa, Italy.

出版信息

J Glob Antimicrob Resist. 2024 Jun;37:176-178. doi: 10.1016/j.jgar.2024.03.017. Epub 2024 Apr 5.

DOI:10.1016/j.jgar.2024.03.017
PMID:38583573
Abstract

OBJECTIVES

To describe at genomic level nine carbapenemase-producing Klebsiella pneumoniae ST307 (Kp-ST307) clinical isolates recovered in Buenos Aires during 2017 to 2021, investigating their resistome, virulome, and phylogeny.

METHODS

Antimicrobial susceptibility was determined according to Clinical and Laboratory Standards Intitute (CLSI). Genomic DNA was sequenced by Illumina MiSeq and analysed using SPAdes, PROKKA, and Kleborate. Phylogeny of 355 randomly selected Kp-ST307 genomes and those from nine local isolates was inferred by a maximum-likelihood approach. The tree was visualized using Microreact.

RESULTS

Besides resistance to ß-lactams and fluoroquinolones, six out of nine Kp-ST307 were also resistant to ceftazidime/avibactam (CZA). This difficult-to-treat resvistance phenotype was mediated by bla and GyrA-83I/ParC-80I mutations in addition to carbapenemase coding genes. Among CZA susceptible isolates, two of them harboured bla while the other harboured bla+bla Regarding CZA-resistant isolates, three harboured bla+bla+bla, two carried bla+bla+bla, and bla+bla were detected in the remaining isolate. Furthermore, five colistin-resistant isolates presented a nonsense mutation in mgrB. Global Kp-ST307 isolates were distributed in two deep-branching lineages while local isolates were set in the main clade of the phylogenetic tree. The five isolates from the same hospital, harbouring bla or bla+bla+bla, clustered in a monophyletic subclade with Italian isolates. Also, an isolate harbouring bla+bla+bla recovered in another hospital was closed to this group. The remaining local Kp-ST307 were grouped in other subclades containing isolates of diverse geographical origin.

CONCLUSION

The inferred resistome was consistent with the resistant phenotype. Phylogeny suggested multiple introduction events in our region and a single major introduction in one hospital followed by local spread.

摘要

目的

描述 2017 年至 2021 年期间在布宜诺斯艾利斯分离的 9 株产碳青霉烯酶肺炎克雷伯菌 ST307(Kp-ST307)的基因组水平,研究其耐药组、毒力组和系统发育。

方法

根据临床和实验室标准协会(CLSI)进行抗菌药物敏感性测定。使用 Illumina MiSeq 对基因组 DNA 进行测序,并使用 SPAdes、PROKKA 和 Kleborate 进行分析。使用最大似然法推断 355 株随机选择的 Kp-ST307 基因组和 9 株本地分离株的系统发育。使用 Microreact 可视化树。

结果

除了对β-内酰胺类和氟喹诺酮类药物的耐药性外,9 株 Kp-ST307 中有 6 株还对头孢他啶/阿维巴坦(CZA)耐药。这种难以治疗的耐药表型是由 bla 和 GyrA-83I/ParC-80I 突变以及碳青霉烯酶编码基因介导的。在 CZA 敏感的分离株中,有 2 株携带 bla,而另 1 株携带 bla。在 CZA 耐药的分离株中,有 3 株携带 bla+bla+bla,2 株携带 bla+bla+bla,在剩余的分离株中检测到 bla+bla。此外,5 株耐多粘菌素的分离株在 mgrB 中存在无意义突变。全球 Kp-ST307 分离株分布在两个深分支谱系中,而本地分离株则位于系统发育树的主要分支中。来自同一医院的 5 株携带 bla 或 bla+bla+bla 的分离株聚集在与意大利分离株的单系亚分支中。另一个医院分离株携带 bla+bla+bla,也与该组关系密切。其余的本地 Kp-ST307 则聚集在其他包含不同地理来源分离株的亚分支中。

结论

推断的耐药组与耐药表型一致。系统发育提示该地区有多次引入事件,其中一次主要引入发生在一家医院,随后发生了本地传播。

相似文献

1
Genomic characterization of carbapenemase-producing Klebsiella pneumoniae ST307 revealed multiple introductions in Buenos Aires, Argentina.产碳青霉烯酶肺炎克雷伯菌 ST307 的基因组特征揭示了在阿根廷布宜诺斯艾利斯的多次传入。
J Glob Antimicrob Resist. 2024 Jun;37:176-178. doi: 10.1016/j.jgar.2024.03.017. Epub 2024 Apr 5.
2
Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307.阿根廷产 KPC 肺炎克雷伯菌的流行情况变化:高黏液性 ST25 和高风险克隆 ST307 的出现。
J Glob Antimicrob Resist. 2019 Sep;18:238-242. doi: 10.1016/j.jgar.2019.06.005. Epub 2019 Jun 13.
3
A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.一株新型 KPC-166 型产头孢他啶/阿维巴坦酶耐药 ST307 肺炎克雷伯菌导致意大利重症监护 COVID 病房爆发。
J Microbiol Immunol Infect. 2024 Jun;57(3):457-469. doi: 10.1016/j.jmii.2024.03.004. Epub 2024 Mar 29.
4
Genomic characterization of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) strains circulating in three university hospitals in Northern Italy over three years.三年间意大利北部三家大学医院流行的产碳青霉烯酶肺炎克雷伯菌(KPC-Kp)菌株的基因组特征。
Antimicrob Resist Infect Control. 2024 Jul 3;13(1):70. doi: 10.1186/s13756-024-01429-x.
5
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23).产KPC的肺炎克雷伯菌临床血培养分离株对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦、亚胺培南/瑞来巴坦耐药的体外活性及基因组特征:一项意大利全国多中心观察性研究(2022 - 23年)
J Antimicrob Chemother. 2025 Feb 3;80(2):583-592. doi: 10.1093/jac/dkae450.
6
Carbapenem-resistant infections in Chinese children: activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study.中国儿童碳青霉烯类耐药感染:头孢他啶-阿维巴坦和氨曲南-阿维巴坦对产碳青霉烯酶菌株活性的双中心研究
Front Cell Infect Microbiol. 2025 Mar 26;15:1545999. doi: 10.3389/fcimb.2025.1545999. eCollection 2025.
7
Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections.头孢他啶-阿维巴坦对血流感染中分离出的产KPC的难治疗肺炎克雷伯菌临床菌株的耐受性和持续性
Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):343-353. doi: 10.1007/s10096-024-05005-4. Epub 2024 Nov 30.
8
A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated .一项大规模监测显示,KPC变体在临床分离菌株中介导对头孢他啶-阿维巴坦的耐药性。
Microbiol Spectr. 2024 Aug 6;12(8):e0025824. doi: 10.1128/spectrum.00258-24. Epub 2024 Jul 3.
9
In-depth characterization of multidrug-resistant NDM-1 and KPC-3 co-producing bloodstream isolates from Italian hospital patients.深入分析来自意大利医院患者的产 NDM-1 和 KPC-3 型多药耐药菌血流分离株。
Microbiol Spectr. 2024 Apr 2;12(4):e0330523. doi: 10.1128/spectrum.03305-23. Epub 2024 Feb 27.
10
Characterization of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae.一种新型KPC-2变体KPC-228的特性分析,该变体使一株ST11-KL64高毒力肺炎克雷伯菌对头孢他啶-阿维巴坦产生耐药性。
Int J Antimicrob Agents. 2025 Mar;65(3):107411. doi: 10.1016/j.ijantimicag.2024.107411. Epub 2024 Dec 19.

引用本文的文献

1
New insights and perspectives on the virulence of hypervirulent Klebsiella pneumoniae.关于高毒力肺炎克雷伯菌毒力的新见解和观点。
Folia Microbiol (Praha). 2025 Apr 8. doi: 10.1007/s12223-025-01261-9.